Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2023-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
2023年半年度关联资金往来情况汇总表
Interim / Quarterly Report Classification · 85% confidence The document is a financial summary table detailing non-operating fund occupation and other related party fund transactions for the half-year period of 2023. It includes specific accounting data such as beginning balances, transaction amounts, interest, repayments, and ending balances for various related parties and subsidiaries. The document is titled as a '2023 half-year summary table' and is approved by the board on August 25, 2023. The content is financial and operational data for a half-year period but does not contain a full interim report with comprehensive financial statements or analysis. The document length is only 2179 characters, which is quite short and more of a financial data summary rather than a full interim or quarterly report. It is not an announcement of a report but a detailed financial summary table. Given the nature and period, this fits best under the category of Interim / Quarterly Report (IR), as it provides substantive financial data for a half-year period, despite being a summary table rather than a full report. Confidence is high due to the clear half-year period and financial data content.
2023-08-25 Chinese
独立董事关于第四届董事会第七次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of 贝达药业股份有限公司 regarding specific matters discussed at the company's fourth board of directors' seventh meeting. It includes opinions on related party transactions, guarantees, and a special report on the use of raised funds for the half-year 2023 period. The document is relatively short (1022 characters) and does not contain full financial statements or comprehensive financial data. It is a formal opinion or statement related to board meeting matters rather than a full report like an Annual Report or Interim Report. It does not fit categories like Audit Report, Earnings Release, or Management Reports. It is not a regulatory filing or announcement of a report publication. The content aligns best with Board/Management Information (MANG), as it concerns board meeting opinions and related disclosures.
2023-08-25 Chinese
2023年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled '贝达药业股份有限公司 2023 年半年度报告摘要' which translates to 'Betta Pharmaceuticals Co., Ltd. 2023 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period of 2023, including revenue, net profit, earnings per share, and asset information. It also discusses business operations, product sales, R&D investments, and shareholder information. The document length is 7010 characters, which is sufficient to contain substantive financial data and analysis. The content is consistent with a comprehensive interim or quarterly financial report rather than a brief announcement or a regulatory filing. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2023-08-25 Chinese
2023年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "贝达药业股份有限公司 2023 年半年度报告全文" which translates to "Betta Pharmaceuticals Co., Ltd. 2023 Semi-Annual Report Full Text." It contains detailed sections including company overview, main financial indicators, management discussion and analysis, corporate governance, environmental and social responsibility, important matters, shareholder changes, preferred shares, bonds, and financial statements. The report period is clearly stated as January 1, 2023 to June 30, 2023, indicating it is a half-year comprehensive financial report. The content includes extensive financial data, management analysis, and operational review, which are characteristic of an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial statements and substantive financial data, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2023-08-25 Chinese
监事会决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of Betta Pharmaceuticals Co., Ltd. regarding the approval of the 2023 semi-annual report and a special report on the use of raised funds. It includes details about the meeting, voting results, and confirms compliance with relevant laws and regulations. The document does not contain the full semi-annual report or detailed financial statements but rather announces the approval and disclosure of these reports elsewhere. The document length is short (1160 characters) and it references that the full reports are disclosed on an external website. Therefore, this is an announcement of the approval and disclosure of reports, not the reports themselves. According to the classification rules, such documents are best classified as Regulatory Filings (RNS) because they do not contain substantive financial data themselves and serve as official announcements of approvals and disclosures.
2023-08-25 Chinese
2023年半年度募集资金存放与使用情况专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the storage and usage of funds raised by the company during the half-year period of 2023. It includes specifics about the amounts raised through initial public offerings and private placements, the use of these funds, changes in investment projects, and compliance with regulatory requirements. The document references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and includes detailed financial tables and project updates. The content focuses on the management and deployment of raised capital rather than general financial performance or earnings. This matches the description of a Capital/Financing Update, which covers company fundraising, financing activities, or capital structure changes. The document is lengthy (15,000 characters) and contains substantive financial data related to fundraising and capital use, not just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-08-25 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.